Medincell to Present at Investor Conferences Amidst Olanzapine LAI Review
Event summary
- Medincell will participate in the Leerink Global Healthcare Conference and Jefferies Biotech on the Beach Summit in Miami, Florida, from March 8-11, 2026.
- CEO Christophe Douat and Chief Strategy Officer Grace Kim will be available for investor meetings.
- Medincell’s risperidone LAI (UZEDY®) received FDA approval for schizophrenia in April 2023 and Bipolar I Disorder in October 2025.
- A New Drug Application (NDA) for Olanzapine LAI, developed in partnership with Teva, was submitted to the FDA in December 2025 and accepted on February 20, 2026.
The big picture
Medincell's strategy of licensing its BEPO® technology to established pharmaceutical companies like Teva allows it to focus on innovation while leveraging their commercial infrastructure. The upcoming FDA decision on Olanzapine LAI represents a significant milestone, potentially validating the platform and opening doors for further partnerships. The long-acting injectable market is experiencing increased demand as clinicians seek to improve patient adherence and outcomes, creating a favorable environment for Medincell's technology.
What we're watching
- Regulatory Risk
- The FDA’s review of Teva’s Olanzapine LAI NDA will be a key catalyst for Medincell’s valuation, and any unexpected delays or requests for additional data could negatively impact investor sentiment.
- Commercial Execution
- How effectively Teva commercializes UZEDY® will directly influence Medincell’s royalty revenue and demonstrate the viability of its BEPO® / BEPO® Star technology platform.
- Pipeline Expansion
- The pace at which Medincell advances its investigational pipeline beyond risperidone and olanzapine will be crucial for long-term growth and diversification of revenue streams.
Related topics